Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART123 in pediatric relapsed/refractory AML
NCT04678336Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Apr 2021
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Phase 1, open-label trial of CART123 in acute myeloid leukemia (AML), sponsored by University of Pennsylvania. Primary endpoint: Safety of CART123 at 5 years. Started Apr 2021; status: terminated.
02
Drugs
CART123
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04678336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04678336.